Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2010

01-12-2010 | Case Report

Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis

Authors: Tomoki Yamano, Eiichi Morii, Isao Arai, Toshiaki Takada, Ken Kubota, Masahiko Sato, Takaaki Inoue, Yoshihiro Okada, Takahiko Hara, Katsuyuki Aozasa

Published in: International Journal of Clinical Oncology | Issue 6/2010

Login to get access

Abstract

Distinguishing primary ovarian cancer from metastatic colorectal cancer is often difficult by a conventional pathological examination alone. We assessed the usefulness of p53 gene mutation analysis for the differential diagnosis of ovarian adenocarcinoma. A 66-year-old woman suffered multiple organ metastases, including the liver, para-aortic lymph node, and right ovary, following an operation for advanced sigmoid colon cancer. She underwent ovarian resection after effective chemotherapy against the liver and para-aortic lymph node cancer. Histological analysis suggested primary ovarian cancer. Therefore, we applied p53 gene mutation analysis for the differential diagnosis of primary versus metastatic ovarian cancer from sigmoid colon cancer. The direct sequence of the p53 gene demonstrated the same gene mutation in codon 211 (ACT to ATT) in both the sigmoid colon and ovarian cancers. According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively. Therefore, we determined that the ovarian tumor was metastatic. Although p53 gene mutation analysis has been applied in some cases, this modality is very useful for the differential diagnosis of primary and metastatic cancer.
Literature
1.
go back to reference Yada-Hashimoto N, Yamamoto T, Kamiura S et al (2003) Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol 89:314–317PubMedCrossRef Yada-Hashimoto N, Yamamoto T, Kamiura S et al (2003) Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol 89:314–317PubMedCrossRef
2.
go back to reference Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92:491–495PubMed Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92:491–495PubMed
3.
go back to reference Salamalekis E, Bakas P, Sykiotis K et al (2004) Outcome of patients with ovarian metastatic tumors. Report of 83 cases and review. Eur J Gynaecol Oncol 25:713–715PubMed Salamalekis E, Bakas P, Sykiotis K et al (2004) Outcome of patients with ovarian metastatic tumors. Report of 83 cases and review. Eur J Gynaecol Oncol 25:713–715PubMed
4.
go back to reference Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222PubMedCrossRef Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222PubMedCrossRef
5.
go back to reference Huang PP, Weber TK, Mendoza C et al (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5:695–698PubMedCrossRef Huang PP, Weber TK, Mendoza C et al (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5:695–698PubMedCrossRef
6.
go back to reference Abu-Rustum N, Barakat RR, Curtin JP (1997) Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol 89:85–87PubMedCrossRef Abu-Rustum N, Barakat RR, Curtin JP (1997) Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol 89:85–87PubMedCrossRef
7.
go back to reference Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRef Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRef
8.
go back to reference Yemelyanova AV, Vang R, Judson K et al (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138PubMedCrossRef Yemelyanova AV, Vang R, Judson K et al (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138PubMedCrossRef
9.
go back to reference Cathro HP, Stoler MH (2002) Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 117:944–951PubMedCrossRef Cathro HP, Stoler MH (2002) Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 117:944–951PubMedCrossRef
10.
go back to reference Park SY, Kim HS, Hong EK et al (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef Park SY, Kim HS, Hong EK et al (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef
11.
go back to reference Logani S, Oliva E, Arnell PM et al (2005) Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 18:19–25PubMedCrossRef Logani S, Oliva E, Arnell PM et al (2005) Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 18:19–25PubMedCrossRef
12.
go back to reference Vang R, Gown AM, Wu LS et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRef Vang R, Gown AM, Wu LS et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRef
13.
go back to reference Oda T, Tsuda H, Scarpa A et al (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674–3678PubMed Oda T, Tsuda H, Scarpa A et al (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674–3678PubMed
14.
go back to reference Noguchi M, Maezawa N, Nakanishi Y et al (1993) Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas. Mol Pathol 2:29–35 Noguchi M, Maezawa N, Nakanishi Y et al (1993) Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas. Mol Pathol 2:29–35
15.
go back to reference Nakazato Y, Tanaka R, Seki E et al (2008) Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report. J Thorac Oncol 3:931–934PubMedCrossRef Nakazato Y, Tanaka R, Seki E et al (2008) Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report. J Thorac Oncol 3:931–934PubMedCrossRef
16.
go back to reference Mok CH, Tsao SW, Knapp RC et al (1992) Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52:5119–5122PubMed Mok CH, Tsao SW, Knapp RC et al (1992) Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52:5119–5122PubMed
17.
go back to reference Russo A, Bazan V, Iacopetta B et al (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528PubMedCrossRef Russo A, Bazan V, Iacopetta B et al (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528PubMedCrossRef
18.
go back to reference Khan ZA, Jonas SK, Le-Marer N et al (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res 6:3499–3504PubMed Khan ZA, Jonas SK, Le-Marer N et al (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res 6:3499–3504PubMed
19.
go back to reference Albanese I, Scibetta AG, Migliavacca M et al (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325:784–791PubMedCrossRef Albanese I, Scibetta AG, Migliavacca M et al (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325:784–791PubMedCrossRef
Metadata
Title
Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis
Authors
Tomoki Yamano
Eiichi Morii
Isao Arai
Toshiaki Takada
Ken Kubota
Masahiko Sato
Takaaki Inoue
Yoshihiro Okada
Takahiko Hara
Katsuyuki Aozasa
Publication date
01-12-2010
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0096-z

Other articles of this Issue 6/2010

International Journal of Clinical Oncology 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine